Long-term case study of myelodysplastic syndrome in a dog.
A 10-year-old, female shih tzu was diagnosed as having myelodysplastic syndrome (MDS) based on the presence of a nonregenerative anemia, dysplastic changes in the three hematopoietic cell lines, a normal to hypercellular bone marrow, and less than 30% blast cells of all nucleated cells in the bone marrow. Low-dose aclarubicin, a differentiation-induction therapy for MDS and atypical leukemias in humans, was administered. Hematological improvement was observed, and the dog lived for 809 days after the first presentation.
Miyamoto
T
T
Department of Veterinary Medicine, College of Agriculture, Osaka Prefecture University, Sakai, Japan.
Horie
T
T
Shimada
T
T
Kuwamura
M
M
Baba
E
E
D015250:Aclarubicin / Q000008:administration & dosage*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001707:Biopsy, Needle / Q000662:veterinary; D001853:Bone Marrow / Q000473:pathology; D002908:Chronic Disease; D004283:Dog Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D017809:Fatal Outcome; D005260:Female; D007275:Injections, Intravenous / Q000662:veterinary; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000662:veterinary*
D000903:Antibiotics, Antineoplastic; D015250:Aclarubicin